Drug intelligence / Profile preview

bli4600

Development stage: Phase 2
Lead developer: Braintree
Modality: Small Molecules
Administration: Oral

Overview

BLI4600 is an experimental oral small molecule drug developed as a bowel preparation agent for colonoscopy. Its precise mechanism of action is unknown. The drug was investigated in clinical trials to evaluate its safety, tolerance, and efficacy in adult patients undergoing colonoscopy. BLI4600 has not been approved for any indication and has no known adverse events reported from trials. The developer is Braintree Laboratories[1][2][3].

Beyond the preview

Go deeper on bli4600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bli4600.

Explore the full profile